What is the recommended treatment for a toe‑nail infection?

Treatment for Toenail Infection (Onychomycosis)

Oral terbinafine 250 mg daily for 12-16 weeks is the first-line treatment for toenail onychomycosis, offering superior cure rates and tolerability compared to all other options. 1

Treatment Algorithm Based on Disease Severity

Severe Onychomycosis (>60% nail involvement)

• Terbinafine 250 mg daily for 12-16 weeks 1, 2
  • Complete cure rate: 55% at 72 weeks
  • Mycological cure maintained in 46% at 5 years
  • Re-evaluate at 3-6 months; continue treatment if disease persists

Moderate Onychomycosis (20-60% nail involvement)

• First choice: Terbinafine 250 mg daily for 12-16 weeks 2
• Alternative: Efinaconazole 10% topical solution (if oral therapy contraindicated) 3
  • Complete cure rate: 3.5 times higher than vehicle
  • Apply daily for 48 weeks

Mild Onychomycosis (<20% nail involvement)

• Efinaconazole 10% topical solution 2
• Alternative: Tavaborole 5% solution 3
  • Apply daily for 48 weeks

Why Terbinafine is Superior

The evidence strongly favors terbinafine over all alternatives 1:

• vs. Itraconazole: Complete cure 55% vs. 26%; mycological relapse 23% vs. 53% at 5 years
• vs. Griseofulvin: Significantly better clinical cure (RR 0.32) and mycological cure (RR 0.64) 4
• Minimal drug interactions: Only affects CYP2D6 substrates
• Better tolerability: Lower discontinuation rates than azoles

Second-Line Oral Options

Itraconazole

• Continuous dosing: 200 mg daily for 12 weeks 1
• Pulse therapy: 400 mg daily for 1 week/month × 3 pulses for toenails
• Use when terbinafine is contraindicated
• More drug interactions (CYP3A4 inhibitor)

Fluconazole (off-label)

• 450 mg weekly for at least 6 months 1
• Lower efficacy than terbinafine or itraconazole
• Consider for patients unable to tolerate first-line agents
• Advantage: Once-weekly dosing improves compliance
• Fewer drug interactions than itraconazole

Topical Therapy Details

FDA-approved topical agents 5:

1. Efinaconazole 10% solution: Highest efficacy among topicals
2. Tavaborole 5% solution: Moderate efficacy, 7.4 times better than vehicle 3
3. Ciclopirox 8% lacquer: Lower efficacy but may be useful for mild cases

Key limitation: Even the best topical treatments achieve complete cure rates of only 15-18%, compared to 55% with oral terbinafine 3

Critical Safety Monitoring

Before Starting Terbinafine

• Baseline liver function tests and CBC required for:
  • Heavy alcohol consumption history
  • Pre-existing hepatitis
  • Hematological abnormalities
  • All pediatric patients (not licensed for children)

Contraindications

• Absolute: Active or chronic liver disease 1
• Relative: Pregnancy, breastfeeding

Important Patient Warnings

• Permanent taste disturbance: Rare but irreversible; counsel all patients 1
• Common side effects: GI symptoms (49%), rash/pruritus (23%)
• Serious adverse events: 0.04% incidence (Stevens-Johnson syndrome, toxic epidermal necrolysis)

Common Pitfalls to Avoid

1. Don't use topical therapy for moderate-to-severe disease: Cure rates are inadequate 3
2. Don't skip mycological confirmation: Always confirm diagnosis before treatment
3. Don't use griseofulvin: Inferior efficacy and higher adverse event rates 4
4. Don't forget re-evaluation: Assess at 3-6 months; nail appearance lags behind mycological cure
5. Don't use oral antibiotics: No role in uncomplicated onychomycosis 6

Device-Based Therapies

1064-nm Nd:YAG laser: Evidence is insufficient; we are uncertain about efficacy and safety 3. Not recommended as primary therapy.

When Oral Therapy is Not an Option

For patients with contraindications to oral antifungals or drug-drug interactions:

• Efinaconazole 10% solution is the best topical alternative
• Set realistic expectations: Lower cure rates (15-18% vs. 55%)
• Treatment duration: 48 weeks minimum
• Consider combination with mechanical debridement

The evidence consistently demonstrates that oral terbinafine provides the best balance of efficacy, safety, and treatment duration for toenail onychomycosis, with topical efinaconazole reserved for mild disease or when oral therapy is contraindicated 1, 3, 4.